Articles tagged with Ulcerative Colitis
Studies presented at the Crohn's & Colitis Congress highlight advancements in treatments for patients with inflammatory bowel disease (IBD), including JAK inhibitors and biologics targeting immune cell trafficking. These therapies show promise for effective and safe oral therapeutic options for moderate to severe ulcerative colitis.
Studies highlight the importance of treating IBD as a whole person, including reproductive and mental health aspects. Patient-provider communication is key to improving health outcomes and addressing emotional exhaustion associated with IBD.
Researchers conducted a randomized study involving 73 adults with mild to moderate active ulcerative colitis, finding that pooled donor FMT induced remission in 32% of patients, compared to 9% with placebo. The study used anaerobically processed stool to preserve bacteria, which survived and administered to patients.
The American Gastroenterological Association publishes a new clinical guideline for managing patients with mild-to-moderate ulcerative colitis. The guidelines recommend the use of oral and topical 5-aminosalicylates, rectal corticosteroids, and oral budesonide to promote high-quality care. However, the use of biologic therapies and imm...
A 20-year study from Northwestern Medicine found men with inflammatory bowel disease have four to five times higher risk of prostate cancer and elevated PSA values. Researchers are now investigating the mechanism behind gut inflammation leading to prostate cancer.
A recent review and analysis of published studies found no consistent association between NSAIDs or acetaminophen use and exacerbation of Crohn's disease. However, a low-bias study showed a link between NSAID use and worsening of Crohn's disease symptoms.
A comprehensive study found that inflammatory bowel disease has become a global disease with accelerating incidence in newly industrialized countries. The research highlights the need for prevention and preparedness measures as these countries struggle to manage this complex and costly disease.
Mucosal healing is crucial in treating ulcerative colitis, as it reduces the risk of colorectal cancer. The study by Flores and colleagues reaffirms that ongoing inflammation increases cancer risk and may impact surveillance colonoscopies.
A six-year study of nearly 1 million people found that autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel diseases increase cardiovascular risk and mortality. The study's results highlight the need for better tools to predict cardiovascular events in these populations.
A new infrared spectroscopy-based blood test may help diagnose ulcerative colitis more effectively and at a lower cost than current colonoscopy methods. Researchers identified nine absorption peaks in mouse blood samples that indicate the presence of the disease.
Researchers found that fecal microbiota transplantation increased bacterial populations resembling healthy donors and reduced inflammatory response. Clinical improvements were seen in 35% of patients and clinical remission in 15%. Further studies are needed to determine long-term effects and optimal delivery methods.
A clinical trial found that yoga significantly improved quality of life and reduced colitis activity in patients with ulcerative colitis. Regular yoga practice is considered a valuable adjunct to conventional medical therapies for managing the condition.
Recent clinical trials show biologics like infliximab and adalimumab promote 28-33% mucosal healing in Crohn's disease and ulcerative colitis. Researchers aim to develop new treatments targeting inflammation differently.
A new biosimilar called CT-P13 has been found safe and effective in treating Crohn's disease and ulcerative colitis, with a clinical response achieved in over 70% of patients at short-term follow-up. The treatment offers a cost-effective alternative to infliximab, a costly biologic therapy.
A study found that nearly one-fourth of ulcerative colitis patients with iron deficiency anemia were untreated, despite being diagnosed. Testing rates varied by region, with lower rates for the Midwest and South.
A genome-wide association study has identified two regions of the genome associated with ulcerative colitis only in people of African descent. The study found unique, African-specific loci and overlapping genome-wide associations for ulcerative colitis and IBD in African-Americans and other populations.
A new review found that certain alternative therapies, such as probiotics and fiber, are effective in treating IBS symptoms. Patients with functional constipation and ulcerative colitis may also benefit from synbiotics and Escherichia coli strain Nissle 1917.
Researchers found that fecal microbiota transplantation effectively treated ulcerative colitis, with 27% of patients achieving symptom-free status. The study, which used a multi-donor approach, showed promise as an alternative treatment option for UC patients resistant to conventional therapies.
The specialty medical home approach aims to provide comprehensive, cost-effective care for patients with inflammatory bowel diseases. This model focuses on patient-centered care, social support, and mental health, addressing high rates of emotional difficulties and poor social support experienced by these patients.
Researchers at UC San Diego School of Medicine showed ozanimod moderately effective in treating ulcerative colitis. Ozanimod reduced rectal bleeding and healed intestinal mucosal lining.
Researchers at Georgia State University have developed a rapid and cost-effective method for detecting ulcerative colitis using Attenuated Total Reflectance Fourier Transform Infrared (ATR-FTIR) spectroscopy. The technique, which involves testing serum for increased presence of mannose, shows promise as a personalized diagnostic tool.
Researchers found that vinegar suppressed inflammation-inducing proteins while improving the gut's bacterial makeup in mice with ulcerative colitis. The study also showed that treatment lowered levels of proteins that induce damaging inflammation, suggesting a potential therapeutic effect.
A study of over 30,000 patients found that Crohn's disease and ulcerative colitis share similar genetic markers, suggesting a continuum of disorders. Genetic data can help identify misdiagnoses and inform treatment guidelines.
A novel protein has been identified as a key player in preventing bowel inflammation, which is a major cause of Crohn's disease and ulcerative colitis. The discovery could lead to the development of targeted therapies for these conditions.
Researchers at Georgia State University develop an oral drug using microparticles and natural herbal molecules to target colon inflammation in ulcerative colitis. The curcumin-loaded microparticles show potential as a scalable drug carrier for efficient clinical treatment of this chronic gastrointestinal disease.
The study identified gene variants within three highly associated regions for Crohn's disease, including NOD2 and interleukin 23 receptor. Additionally, the researchers found novel regions of chromosomes 2 and 3 to be causative for IBD in African-Americans.
A new study from the University of Toronto found that adults with ulcerative colitis were twice as likely to have childhood physical or sexual abuse, with one-quarter reporting physical abuse and one-fifth reporting sexual abuse. The study also found no association between childhood maltreatment and Crohn's disease.
A study by University of Toronto researchers found that individuals with Crohn's disease or ulcerative colitis are twice as likely to develop generalized anxiety disorders. Women with IBD have four times the odds of anxiety compared to men, highlighting the need for targeted interventions.
Patients over 50 with ulcerative colitis who undergo elective colectomy live longer than those treated with medications, according to a new study. The study found that surgery was associated with an improved survival rate, particularly in patients age 50 and over.
Studies show that certain bacterial groups in the gut can help protect against inflammation and control symptoms of UC. Researchers found that fecal microbiota transplantation with specific beneficial bacteria may be a promising treatment option for UC.
A study found that patients with ulcerative colitis spend an average of 5.5 hours researching surgical options before meeting with their doctor. Patients reported that while doctors provide the most believable information, it is often the least helpful, emphasizing the need for improved decision-support tools.
A new study suggests that Symprove, a live multi-strain probiotic drink, can reduce intestinal inflammation in patients with ulcerative colitis. The results show significant reductions in faecal calprotectin levels and improvements in symptoms without observed side effects.
The Crohn's & Colitis Foundation is establishing the world's largest database for Crohn's disease and ulcerative colitis research, which will integrate patient information, genetic profiles, and clinical data. The $17.5 million initiative aims to speed progress toward precision medicine and potential cures.
A new study found that both short and long sleep durations are associated with an increased risk of developing ulcerative colitis. The study, published in Clinical Gastroenterology and Hepatology, followed over 90% of nurses for biennial questionnaires to examine the association between sleep duration and incident disease.
Researchers have discovered a link between genetic factors and the development of early-onset ulcerative colitis. The study's findings suggest that phosphatase and tensin homologue (PTEN) may play a role in helping the disease develop, and that altering the gut microbiome could be a key to prevention.
The collaboration aims to understand the underlying genetics of IBD and potentially lead to new treatments. All study participants will receive 23andMe's Personal Genome Service at no cost.
New research suggests that mango consumption may reduce inflammation in ulcerative colitis and promote bone health in ovariectomized mice. Mango polyphenolics also showed potential in modifying microbiota and short chain fatty acid production in rats with DSS-induced colitis.
The GEMINI studies found vedolizumab to be an effective treatment for patients with moderately to severely active Crohn's disease and ulcerative colitis. The study suggests that the drug may provide people living with these conditions an additional option for inducing and maintaining clinical remission.
Two studies found that vedolizumab resulted in remission and reduced use of prednisone for patients with moderate-to-severe Crohn's disease and ulcerative colitis. The medication blocks immune system cells that trigger inflammation, reducing side effects commonly associated with other treatments.
Research finds that voluntary wheel running reduces pro-inflammatory gene expression in the colon, while forced treadmill running increases it. Forced exercise also disrupts the gut's microbial environment.
University of Cincinnati researchers have discovered biomarkers for inflammatory bowel disease (IBD), a group of inflammatory conditions affecting the colon and small intestine. These biomarkers, identified through analysis of human serum specimens from the Department of Defense Serum Repository, may help improve diagnosis and treatmen...
Researchers demonstrated PET/CT's ability to identify lesions along the complete intestinal wall, detecting advanced inflammatory changes and unmasking subepithelial disease activity. The technique showed promise in serially assessing IBD activity, potentially benefiting patients with chronic-remittent conditions.
Fecal microbial transplantation has been shown to improve symptoms in most pediatric patients with active ulcerative colitis, with 78% achieving clinical response within one week. The procedure involves infusion of human stool from a healthy donor into the intestine of the patient to restore healthy microbial flora.
A new study identifies 71 additional genetic associations for IBD, many linked to immune-related disorders. Researchers found a strong overlap between IBD susceptibility genes and genes responding to mycobacterial infections.
Researchers at Scripps Research Institute have developed a new technology that can identify potential biomarkers for ulcerative colitis in animal models. The study focuses on protein arginine deiminases (PAD) and their role in diseases such as cancer, multiple sclerosis, and rheumatoid arthritis.
A phase 2 clinical trial has identified a potential new class of drug that achieves clinical response and remission in certain patients with moderate-to-severe ulcerative colitis. The study, conducted at the University of California San Diego, shows oral treatment with Tofacitinib to be effective.
Researchers at NYU School of Medicine are enrolling patients in a clinical trial testing the use of worm eggs to relieve symptoms of ulcerative colitis. The trial aims to understand how worm eggs may improve symptoms by altering the lining of the intestine and changing the type of bacteria attached.
Combining VSL#3 with traditional therapies increases remission rates by 10-17% and initiates remission 47-69% faster. This combination is also more effective than using anti-inflammatory drugs alone.
Researchers discovered that fungi inhabit the large intestine and play a role in inflammatory diseases like ulcerative colitis. The study identified a protein called Dectin-1, which helps protect against inflammation caused by indigenous fungi.
New research presents key insights into preventing and treating bowel diseases, which affect millions worldwide. Studies show that dietary additives, hormone replacement therapy, and even high-altitude travel may cause or exacerbate these diseases.
A new study on Inflammatory Bowel Disease (IBD) in Canadian First Nations people reveals distinct genetic variations and immune response patterns compared to white populations. The research found lower numbers of genetic variants involved in recognizing bacteria, potentially impacting the disease's progression.
Sigma-Tau Pharmaceuticals is sponsoring a Patient Assistance Program (PAP) to provide financial assistance for VSL#3 DS, a prescription-only double strength probiotic formulation, to eligible patients with ulcerative colitis or ileal pouch. The program aims to make it easier for those in need to access the probiotic medical food.
A team of researchers has pinpointed an amino acid variation in the immune response gene DRB1 as a key factor in ulcerative colitis. This association was confirmed using sophisticated association techniques and suggests that the gene plays a significant role in determining the human immune response to extracellular antigens.
Researchers identified a gene expression profile that can predict prognosis in patients with inflammatory bowel disease. The study found two subgroups of patients, one with mild disease and the other with treatment-nonresponsive disease, which will help physicians identify those who need aggressive therapies.
The majority of potential patients are eager for fecal microbiota transplantation to become available, despite concerns about donor selection and screening. Patients view the treatment as 'natural' and easier than currently available therapies.
Researchers identify IL-23 as a major contributor to inflammation in Crohn's disease and ulcerative colitis, offering hope for new treatments. The study provides insight into the pathogenic role of IL-23 and its potential as a therapeutic target.
A new study has linked 29 genome regions to ulcerative colitis, a common form of inflammatory bowel disease. The research identified genes involved in the immune response and provided insights into the biology underlying the disease.
A new Confocal Laser Endomicroscope (CLE) tool allows clinicians to view bacteria that trigger bowel diseases like Crohn's and ulcerative colitis during routine colonoscopy. This enables rapid identification of patients at risk or in early stages of these diseases.
Researchers discover that infection with Trichuris trichiura eggs increases mucus production in the colon, providing symptomatic relief from ulcerative colitis. The study identifies a shift from pro-inflammatory to anti-inflammatory immune cells, paving the way for potential helminth therapy.
Research found that adults diagnosed with ulcerative colitis at age 50 or later had better disease outcomes, including higher remission rates, compared to those diagnosed earlier in life. The study suggests changes in the aging immune system and environmental factors like smoking may contribute to this phenomenon.